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T he anaplastic lymphoma kinase (ALK) gene is located on chromosome 2p23 and expressed in 
fetal neural cells.  The ALK gene is phosphorylated and 
activated to control cell proliferation,  survival,  and 
differentiation during the development of the nervous 
system [1].  ALK t(2 ; 5) chromosomal translocation 
was first reported in anaplastic large cell lymphomas 
(ALCLs) in 1994 [2].  ALCL,  also known as Ki-1 lym-
phoma or large-cell anaplastic lymphoma,  is a subtype 
of human non-Hodgkin’s lymphoma that is character-
ized by the expression of CD30 (Ki-1 antigen) and a 
peculiar large anaplastic morphology that mimics 
Reed-Sternberg cells [3 , 4].  The t(2 ; 5)(p23 ; q35) 
chromosomal translocation,  which forms the nucleop-
hosmin (NPM)-ALK chimeric protein (p80NPM/ALK),  was 
first reported in Japan [5 , 6] and the United States [7].  
Shiota et al.  also report that p80-positive ALCL is a 
distinct entity both clinically and pathogenetically and 
should be differentiated from p80-negative ALCL [8].  
Subsequently,  more than 25 patterns of ALK fusion 
partners have been reported [9 , 10].  In 2007 in Japan,  
the echinoderm microtubule-associated protein-like 4 
(EML4)- ALK fusion gene was found to cause lung can-
cer [11].  This gene has been discovered in about 3-5% 
of non-small cell lung cancer (NSCLC) patients [12].  
ALK tyrosine kinase is automatically activated by mul-
timerization with fusion partners,  causing cancers 
through the overexpression of cell proliferation signals.  
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The prognosis of advanced non-small cell lung cancer (NSCLC) patients has improved in recent decades,  espe-
cially for patients with an oncogenic driver mutation.  Anaplastic lymphoma kinase (ALK) tyrosine kinase 
inhibitors (TKIs) are effective for patients with the echinoderm microtubule-associated protein-like 4-ALK fusion 
gene.  Several ALK-TKIs have been established: the first-generation ALK-TKI,  crizotinib; second-generation 
ALK-TKIs,  alectinib and ceritinib; and third-generation ALK-TKI,  lorlatinib.  Some ALK-TKIs are effective 
for tumors that are resistant to other ALK-TKIs; however,  as is known in epidermal growth factor receptor- 
mutant lung cancer,  tumor resistance is inevitable.  ALK-positive NSCLCs acquire resistance via various mech-
anisms,  making it a heterogeneous disease.  Therefore,  it is necessary to develop next-generation treatment 
strategies,  such as the use of next-generation ALK-TKIs for secondary mutations,  or combination therapies 
with ALK-TKIs and other TKIs.  In this review,  we summarize the development and use of ALK-TKIs,  prior 
pivotal clinical trials,  and resistance mechanisms.
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Hence,  a blockade of ALK tyrosine kinase activation 
significantly inhibits cell proliferation in ALK fusion 
gene-positive cancer.  Subsequently,  several ALK tyro-
sine kinase inhibitors (TKIs) have been developed and 
evaluated for efficacy in pivotal EML4-ALK-positive 
NSCLC clinical trials.  A total of four ALK-TKIs are 
currently approved in Japan: the first-generation ALK-
TKI crizotinib; second-generation ALK-TKIs alectinib 
and ceritinib; and third-generation ALK-TKI lorlati-
nib.  Notably,  the second-generation ALK-TKI alectinib 
showed a high objective response rate (93.5%) and long 
progression-free survival (3-year progression-free sur-
vival rate: 62%) for ALK-positive NSCLC [13].  In addi-
tion,  alectinib is associated with fewer severe adverse 
effects such as diarrhea and nausea than crizotinib 
(described below) [14 , 15].  Thus,  alectinib is widely 
used as the first-line treatment in ALK-positive lung 
cancer patients.  However,  acquired resistance is inevi-
table,  and is an important clinical issue.  In this review,  
we summarize the development of ALK-TKIs,  prior 
pivotal clinical trials,  and mechanisms of resistance to 
ALK-TKIs.
The Development of ALK-TKIs and Results of 
Pivotal Clinical Trials
Crizotinib. Crizotinib was the first molecular- 
targeted drug approved for EML4-ALK fusion-positive 
NSCLC.  It was approved in 2012 based on the PROFILE 
1007 study,  a randomized phase 3 trial comparing 
crizotinib with standard cytotoxic chemotherapy 
(pemetrexed or docetaxel) in patients with locally 
advanced or metastatic ALK-positive lung cancer who 
had previously received one platinum-based regimen 
[16].  Patients were randomly assigned to the crizotinib 
arm (n = 173) or the standard chemotherapy arm 
(n = 174: pemetrexed 58%,  docetaxel 42%).  The pri-
mary endpoint was median progression-free survival 
(mPFS),  which was 7.7 months in the crizotinib arm 
and 3.0 months in the chemotherapy arm (hazard ratio 
[HR],  0.49; 95% confidence interval [CI],  0.37-0.64;  
p < 0.001).  Subsequently,  in 2014,  a phase 3 trial com-
paring the mPFS with crizotinib in cytotoxic chemo-
therapy as the first-line therapy in patients with 
advanced ALK-positive NSCLC (PROFILE1014) was 
reported (Table 1) [17 , 18].  In the PROFILE1014 study,  
the primary endpoint was mPFS,  which was 10.9 
months in the crizotinib arm and 7.0 months in the 
chemotherapy arm (HR 0.45; 95% CI,  0.35-0.60;  
p < 0.001).  Based on this result,  crizotinib was 
approved as the first-line treatment for ALK-positive 
advanced NSCLC.  Although crizotinib was the first 
approved drug for treating ALK-positive NSCLC,  it has 
some limitations with regard to its safety profile i.e.,  it 
causes visual impairment,  diarrhea,  vomiting,  and liver 
damage.  Adverse effects arise because crizotinib inhib-
its not only ALK but also other kinases such as MET 
proto-oncogene,  receptor tyrosine kinase (MET),  and 
c-ROS oncogene 1 (ROS1).  Crizotinib has been approved 
for ROS1 fusion gene-positive NSCLCs [19 , 20].
Alectinib. The second-generation ALK-TKI alec-
tinib was first approved in Japan in 2014.  First,  two 
phase 1/2 trials were conducted: the AF-001JP trial for 
crizotinib-untreated patients,  and the AF-002JG trial 
for crizotinib-resistant patients (Table 2).  Although 
these trials were single-arm studies,  alectinib showed an 
unprecedented high response rate (93.5%),  a long 
mPFS (not reached),  and a high 3-year PFS rate (62%) 
in the AF-001JP trial [13 , 21],  and a high response rate 
(55%) in the AF-002JG trial [22].  Based on these prom-
ising results,  two phase 2 trials were conducted to 
investigate the anti-tumor activity of alectinib for crizo-
tinib-resistant ALK-positive NSCLCs.  Ou et al.  report 
that the response rate was 50% (95%CI,  41-59%) and 
the mPFS was 8.9 months (95%CI,  5.6-11.3 months) 
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Table 1　 Prior pivotal randomized phase 3 clinical trials on ALK-positive non-small-cell lung cancer (NSCLC) (ALK-TKI naive)
Study name Ref. ALK-TKI Comparative arm Treatment line
Patients 
(n)
mPFS
(months)
PFS HR [95% CI] mOS
(months)
OS HR [95% CI]
PROFILE1014 [17 ,18] Crizotinib Chemotherapy Naïve 172 10.9 vs 7.0 0.45 [0.35-0.60] NR vs 47.5 0.346 [0.081-0.718]
J-ALEX [14 ,25] Alectinib Crizotinib ALK-TKI naïve 103 34.1 vs 10.2 0.37 [0.26-0.52] NR vs 43.7 0.80 [0.35-1.82]＊
ALEX [15 ,26] Alectinib Crizotinib Naïve 152 34.8 vs 10.9 0.43 [0.32-0.58] NR vs NR 0.76 [0.50-1.15]
ASCEND-4 [30] Ceritinib Chemotherapy Naïve 189 16.6 vs 8.1 0.55 [0.42-0.73] NR vs 26.2 0.73 [0.50-1.08]
ALTA-1L [36] Brigatinib Crizotinib ALK-TKI naïve 137 NR vs 9.8 0.49 [0.33-0.74] NR vs NR 0.98 [0.50-1.93]
ALK,  anaplastic lymphoma kinase; TKI,  tyrosine kinase inhibitor; mPFS,  median progression-free survival; HR,  hazard ratio; CI,  confidence interval; mOS,  median 
overall survival; NR,  not reached.
＊99.8799% CI
[23].  Shaw et al.  also obtained similar results,  reporting 
a response rate of 48% (95%CI,  36-60%) and mPFS of 
8.1 months (95%CI,  6.2-12.6 months) [24].  Subsequently,  
two randomized phase 3 trials were conducted to com-
pare the mPFS of alectinib with that of crizotinib in 
ALK inhibitor-naive ALK-positive NSCLC patients 
(Table 1).  The first study,  the J-ALEX trial,  conducted 
in Japan,  showed significant prolongation of mPFS in 
the alectinib arm (300 mg twice daily) (alectinib for 
34.1 months vs. crizotinib for 10.2 months; HR,  0.37;  
95%CI,  0.26-0.52; p < 0.0001) [14 , 25],  and the occur-
rence of grade 3 or 4 adverse events was more frequent 
with crizotinib (60.6%) than with alectinib (36.9%).  
Another study,  the ALEX trial,  was conducted as a 
global phase 3 study excluding Japan.  In this trial,  the 
PFS rate was significantly higher in the alectinib arm 
(600 mg twice daily) than in the crizotinib arm (1-year 
event-free survival rate,  68.4% [95%CI,  61.0-75.9] vs. 
48.7% [95%CI,  40.4-56.9]; p < 0.001),  and the mPFS 
with alectinib was 34.8 months compared to 10.9 
months with crizotinib (HR 0.43,  95%CI,  0.32-0.58;  
p < 0.001) [15 , 26].  In addition,  tumor progression to 
the central nervous system was less frequent in the alec-
tinib group (12%) compared to the crizotinib group 
(45%).  Consequently,  alectinib was recommended as 
the first-line therapy for ALK-positive advanced NSCLCs.
Ceritinib. Another second-generation ALK-TKI,  
ceritinib,  was approved in 2016.  The ASCEND-1 trial 
was a phase 1 clinical trial to assess the efficacy of ceri-
tinib in ALK inhibitor-pretreated and ALK inhibitor- 
naïve NSCLC patients [27 , 28].  The overall response 
rate was 56.4% (95%CI,  48.5-64.2%) in ALK inhibi-
tor-pretreated patients (n = 163) and 72.3% (95%CI,  
61.4-81.6%) in ALK inhibitor-naïve patients (n = 83).  
The median PFS was 6.9 months (95%CI,  5.6-8.7 
months) in ALK inhibitor-pretreated patients and 18.4 
months (95%CI,  11.1-not reached (NR)) in ALK inhib-
itor-naïve patients.  Next,  the ASCEND-2 phase 2 trial 
was conducted to evaluate efficacy and safety in ALK-
positive NSCLC patients who had been treated with at 
least one platinum-based chemotherapy and had expe-
rienced tumor progression after crizotinib treatment 
[29] (Table 2).  The overall response rate was 38.6% 
(95%CI,  30.5-47.2%),  and the mPFS was 5.7 months 
(95%CI,  5.4-7.6 months); therefore,  ceritinib was 
approved for crizotinib-resistant ALK-positive NSCLCs.  
Randomized phase 3 trials were subsequently conduct-
ed: the ASCEND-4 and ASCEND-5 trials.  The 
ASCEND-4 trial,  which compared first-line ceritinib 
with platinum-based chemotherapy (cisplatin or carbo-
platin/pemetrexed),  showed that mPFS was 16.6 
months (95%CI,  12.6-27.2) in the ceritinib arm and 8.1 
months (95%CI,  5.8-11.1) in the chemotherapy arm 
(HR 0.55,  95%CI,  0.42-0.73; p < 0.00001) (Table 1) 
[30].  After that,  ceritinib was approved for ALK inhib-
itor-naïve NSCLC in 2017.  The ASCEND-5 trial,  
which compared ceritinib with chemotherapy (peme-
trexed or docetaxel) in patients who had previously 
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Table 2　 Prior pivotal clinical trials on ALK-positive non-small-cell lung cancer (NSCLC) (ALK-TKI pretreated)
Study name Ref. First Author Phase Prior treatment ALK-TKI
Patients 
(n)
ORR (%)
[95% CI]
mPFS (months)
[95% CI]
mOS (months)
[95% CI]
AF002JG [22] Gadgeel SM 1/2 Crizotinib Alectinib 47 55 NA NA
Alectinib [23] Ou SH 2 Crizotinib Alectinib 138 50 [41-59] 8.9 [5.6-11.3] NA
Alectinib [24] Shaw AT 2 Crizotinib Alectinib 87 48 [36-60] 8.1 [6.2-12.6] NA
ASCEND-1 [28] Kim DW 1 Crizotinib Ceritinib 163 56.4 [48.5-64.2] 6.9 [5.6-8.7] 16.7 [14.8-NR]
ASCEND-2 [29] Crino L 2 Platinum doublet
Crizotinib
Ceritinib 140 38.6 [30.5-47.2] 5.7 [5.4-7.6] 14.9 [13.5-NR]
ASCEND-5 [31] Shaw AT 3 Platinum doublet
Crizotinib
Ceritinib or
PEM/DOC
115
116
39.1 [30.2-48.7]
6.9 [3.0-13.1]
5.4 [4.1-6.9]
1.6 [1.4-2.8]
18.1 [13.4-23.9]
20.1 [11.9-25.1]
ASCEND-9 [32] Hida T 2 Alectinib ±
Crizotinib
Ceritinib 20 25 [8.7-49.1] 3.7 [1.9-5.3] NA
Lorlatinib [33] Shaw AT 1 ALK-TKI Lorlatinib 41 46 [31-63] 9.6 [3.4-16.6] NA
Lorlatinib [34] Solomon BJ 2 228
　EXP2-3A Crizotinib Lorlatinib 59 69.5 [56.1-80.8] NR [12.5-NR] NA
　EXP3B Other ALK-TKI Lorlatinib 28 32.1 [15.9-52.4] 5.5 [2.7--9.0] NA
　EXP4-5 2-3 ALK-TKI Lorlatinib 111 38.7 [29.6-48.5] 6.9 [5.4-9.5] NA
ALTA [35] Camidge DR 2 Crizotinib Brigatinib (90)
Brigatinib (180)
112
110
40 [29-52]
59 [47-70]
8.8 [5.6-11.1]
12.9 [9.3-NR]
NR [NR-NR]
NR [17.8-NR]
ALK,  anaplastic lymphoma kinase; TKI,  tyrosine kinase inhibitor; ORR,  objective response rate; mPFS,  median progression free survival; mOS,  median overall 
survival; NR,  not reached; PEM,  pemetrexed; DOC,  docetaxel; NA,  not accessed.
received chemotherapy and crizotinib,  demonstrated 
that ceritinib yielded a significant improvement in 
mPFS compared to chemotherapy (5.4 months [95%CI,  
4.1-6.9] for ceritinib vs. 1.6 months [95%CI,  1.4-2.8] 
for chemotherapy; HR 0.49 [0.36-0.67]; p < 0.0001) 
(Table 2) [31].  The ASCEND-9 trial was conducted to 
examine ceritinib efficacy for alectinib-resistant ALK-
positive NSCLC.  A total of 20 alectinib-resistant 
patients were enrolled in this prospective phase 2 study,  
which found an overall response rate of 25% 
(95%CI: 8.7-49.1),  a disease control rate of 70.0% 
(95%CI: 45.7-88.1),  and mPFS of 3.7 months (95%CI:  
1.9-5.3) (Table 2) [32].  No trial has yet compared the 
effects of ceritinib with those of alectinib.  However,  
ceritinib has more frequent gastrointestinal toxicities 
than alectinib (the ALEX study),  including diarrhea 
(85% vs. 12%),  nausea (80% vs. 14%),  and vomiting 
(65% vs. 7%).  Therefore,  ceritinib is considered a sal-
vage treatment option for crizotinib- or alectinib-resis-
tant ALK-positive lung cancers.
Lorlatinib. The third-generation ALK-TKI lorla-
tinib was developed as a selective and brain-penetrant 
ALK inhibitor.  In a phase 1 study,  which was a single- 
arm,  first-in-human dose-escalation study,  lorlatinib 
demonstrated an objective response in 19/41 patients 
(46%; 95%CI: 31-63) who had received two or more 
ALK-TKIs [33].  A subsequent global phase 2 study was 
conducted to evaluate the efficacy of lorlatinib.  ALK-
positive NSCLC patients were enrolled into different 
expansions as follows: ALK treatment-naïve (EXP1,  
n = 30); previously received crizotinib without (EXP2,  
n = 27) or with (EXP3A; n = 32) chemotherapy; re-
ceived one previous non-crizotinib ALK-TKI,  with or 
without chemotherapy (EXP3B,  n = 28); received two 
(EXP4,  n = 66) or three (EXP5,  n = 46) previous ALK-
TKIs with or without chemotherapy (Table 2).  The 
primary endpoint was overall and intracranial tumor 
response.  In the EXP1 group,  the objective response 
rate was 27/30 (90.0%; 95%CI,  73.5-97.9),  and intra-
cranial responses were observed in 2/3 of patients 
(66.7%; 95%CI,  9.4-99.2).  In the EXP2-5 groups,  the 
objective response rate was 93/198 (47.0%; 95%CI,  
39.9-54.2),  and intracranial responses were observed in 
51/81 patients (63.0%; 95%CI,  51.5-73.4).  In the sub-
group analysis,  the objective response rate was 41/59 
(69.5%; 95%CI,  56.1-80.8) in EXP2-3A,  9/28 (32.1%;  
95%CI,  15.9-52.4) in EXP3B,  and 43/111 (38.7%;  
95%CI,  29.6-48.5) in EXP4-5.  Objective intracranial 
response was achieved in 20/23 patients (87.0%;  
95%CI,  66.4-97.2) in EXP2-3A,  5/9 (55.6%; 95%CI,  
21.2-86.3) in EXP3B and 26/49 (53.1%; 95% CI,  38.3-
67.5) in EXP4-5 [34].  Thus,  lorlatinib was approved in 
2018 for ALK-TKI-resistant or intolerant ALK-positive 
NSCLCs.  In this trial,  relatively unique adverse effects 
were observed,  such as hypercholesterolemia (81%),  
hypertriglyceridemia (60%) edema (43%),  and cogni-
tive defects (18%).  A randomized phase 3 study,  the 
CROWN trial (NCT03052608),  comparing lorlatinib 
with crizotinib as a first-line treatment for ALK-positive 
NSCLC patients,  is now recruiting.
Brigatinib. The approval of brigatinib was accel-
erated in the United States in April 2017 for the treat-
ment of ALK-positive NSCLC patients who had resis-
tance to or were intolerant to crizotinib.  A randomized 
phase 2 trial,  ALTA,  was the rationale for this approval 
(Table 2) [35].  In this study,  crizotinib-resistant ALK-
positive advanced NSCLC patients were randomly 
assigned (1 : 1) to receive brigatinib at 90 mg once daily 
(arm A) or 180 mg once daily with a 7-day lead-in at 
90 mg (arm B).  The objective response rate,  mPFS,  
and median overall survival were 32/80 (40%; 95%CI,  
29-52),  8.8 months (95%CI,  5.6-11.1),  and NR (95%CI,  
NR-NR) in arm A,  respectively,  and 43/73 (59%;  
95%CI,  47-70),  12.9 months (95%CI,  9.3-NR) and NR 
(95%CI,  17.8-NR) in arm B.  In patients with brain 
metastases,  the intracranial objective response rate was 
12/26 (46%; 95%CI,  27-67) in arm A,  and 12/18 (67%;  
95%CI,  41-87) in arm B.  Thus,  brigatinib yielded sub-
stantial intracranial responses in crizotinib-resistant 
ALK-positive NSCLC.  In the first-line setting,  the 
ALTA-1L randomized phase 3 trial was conducted to 
compare brigatinib with crizotinib for the treatment of 
ALK inhibitor-naïve ALK-positive NSCLC patients 
(Table 1) [36].  The mPFS,  which was the primary end-
point,  was NR in the brigatinib arm and 9.8 months 
(95%CI,  9.0-12.9) in the crizotinib arm (HR 0.49;  
95%CI,  0.33-0.74; p < 0.001).  In Japan,  a single-arm,  
multicenter,  phase 2 study of brigatinib in Japanese 
patients with ALK-positive NSCLC (NCT03410108) is 
currently recruiting to evaluate the efficacy of brigatinib.
Mechanisms of Drug Resistance to Alectinib
Primary resistance to ALK-TKIs. Although there 
have been few reports on primary resistance to alec-
tinib,  several cases of primary resistance to crizotinib 
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have been reported [37],  with the following reported 
primary resistance mechanisms: MYC amplification 
[38],  a new ALK fusion partner (Cap methyltransfer-
ase 1-ALK fusion) [39],  epidermal growth factor 
receptor (EGFR) mutation [40 , 41],  KRAS mutation 
[42] and BIM polymorphism [43].  These primary resis-
tances are relatively rare compared to the secondary 
resistance discussed below; hence,  their precise mech-
anisms have not yet been clarified.
Secondary resistance to alectinib. As in the case 
of other molecular-targeted therapies for advanced 
NSCLC,  acquired resistance to ALK-TKI is an inevita-
ble clinical problem.  Alectinib is recommended as the 
first-line therapy for ALK-positive advanced NSCLCs;  
we therefore focus on resistance to alectinib in this sec-
tion.  To date,  several mechanisms of resistance to alec-
tinib,  such as secondary resistance ALK mutations [44-
49],  bypass track activation via MET gene amplification 
[50 , 51],  MET activation via hepatocyte growth factor 
autocrine stimulation [52],  EGFR ligand amphiregulin 
overexpression [51],  and transformation to small-cell 
lung cancer [53-55] have been reported in clinical sam-
ples (Figure 1).  Several types of secondary resistance 
ALK mutations have been reported.  Secondary resis-
tance mutations to alectinib,  which is widely used as a 
first-line TKI treatment for ALK-positive NSCLC,  
include I1171N,  G1202R,  I1171S,  I1171T,  and V1180L 
[48 , 56].  Of these secondary mutations,  all other than 
G1202R are sensitive to ceritinib or lorlatinib,  and the 
G1202R mutation is sensitive to lorlatinib [57].
After sequential ALK-TKI treatment,  compound 
ALK mutations can occur.  Yoda et al.  report that 
sequential ALK-TKIs may induce the emergence of 
compound ALK mutations [58],  and several compound 
mutations have been found,  such as L1196M + G1202R 
and C1156Y + L1198F.  In addition,  interestingly,  the 
C1156Y mutation is known as a crizotinib-resistant 
mutation,  while the C1156Y + L1198F compound 
mutation,  which occurs after crizotinib-lorlatinib 
sequential therapy,  is sensitive to crizotinib [59].  
Okada et al.  recently reported the sensitivity of ALK 
inhibitors for compound ALK mutations using in silico 
simulation.  In their study,  the I1171N + L1256F com-
pound mutation was found to be highly resistant to 
lorlatinib but more sensitive to alectinib than the 
I1171N mutation alone.  The L1256F mutation was the 
first highly lorlatinib-resistant single mutation but,  
interestingly,  it is highly sensitive to alectinib [60].  
Thus,  variations in ALK secondary mutations are very 
complicated.
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Fig. 1　 Alectinib-resistant mechanisms.  
EML4-ALK-positive NSCLCs acquire resis-
tance by several mechanisms: (i) ALK 
secondary change,  (ii) Bypass track activa-
tion,  (iii) Other mechanisms.
Rapidly acquired resistance to alectinib. Alectinib 
is considered the standard therapy for patients with 
NSCLC harboring ALK fusion genes.  However,  some 
patients rapidly acquire resistance to alectinib,  resulting 
in highly unfavorable prognoses.  The underlying 
mechanisms for rapid resistance to alectinib remain to 
be clarified,  but we previously reported that a high 
tumor mutation burden could be a contributing factor 
[51].  In our previous report,  we used next-generation 
sequencing to analyze ALK-positive clinical samples 
(treatment-naïve samples and autopsy samples) from 
one patient who developed rapid resistance to alectinib 
within 3 months.  Our comprehensive analysis revealed 
the heterogeneous tumor evolution of autopsy samples 
compared to treatment-naïve samples.
Treatment Strategy for ALK-positive Lung 
Cancer
Based on pivotal clinical studies,  mild adverse effects,  
and a stunning disease control rate,  alectinib is often 
used as the first-line ALK-TKI.  Regarding second-line 
therapy,  several sequential ALK-TKI treatment trials 
have been reported to date (Table 2).  Nevertheless,  
there are limited data on the efficacy of ALK-TKIs after 
resistance to alectinib has been acquired.  Therefore,  
there is no definite treatment sequence used in ALK-
TKI treatment at present.
When resistance is induced by a secondary mutation 
in the ALK kinase domain,  a second- or third-genera-
tion ALK-TKI such as ceritinib,  brigatinib,  or lorlatinib 
is expected to overcome the resistance.  Notably,  
G1202R,  a highly resistant mutation to first- and sec-
ond-generation ALK-TKIs,  is sensitive to the third- 
generation ALK-TKI lorlatinib.  The G1202R mutation 
is more frequently observed in alectinib-resistant spec-
imens than in crizotinib- or ceritinib-resistant speci-
mens [56]; hence,  alectinib followed by lorlatinib may 
be the best ALK-TKI sequence in such cases.  Where 
resistant mutations other than G1202R are present,  
such as I1171T/N/S,  V1180L,  or L1196M,  ceritinib 
may also be useful as a second-line treatment [56].  On 
the other hand,  for patients who acquired resistance via 
bypass pathway activation,  crizotinib (for MET gene 
amplification),  ceritinib (for insulin-like growth factor 
[IGF]-1R activation),  and alectinib or lorlatinib (for 
P-glycoprotein overexpression) [61] are the candidates 
of choice for second-line treatment.
The identification of the best treatment sequence or 
combination therapies for drug-resistant lung cancer 
has been a challenge [58].  Currently,  several combina-
tion therapies with ALK-inhibitors and other molecu-
lar-targeting agents developed for lung cancers are 
ongoing in clinical trials.  These include the following:  
1) MEK-inhibitors: NCT03202940,  alectinib combined 
with cobimetinib; NCT03087448,  ceritinib combined 
with trametinib; 2) anti-vascular endothelial growth 
factor (VEGF) antibodies: NCT02521051,  alectinib 
combined with bevacizumab; and 3) immunotherapy:  
NCT02393625,  ceritinib combined with nivolumab;  
NCT01998126,  crizotinib combined with nivolumab or 
ipilimumab; NCT02013219,  alectinib combined with 
atezolizumab.  Regarding combination therapy with 
ALK-TKIs and immune checkpoint inhibitors,  Group E 
in the CheckMate 370 study was the phase 1/2 cohort 
testing the safety and tolerability of crizotinib plus 
nivolumab as a first-line treatment for ALK-positive 
NSCLC.  However,  5/13 patients (38%) developed 
severe hepatic toxicities,  and two died,  leading to dis-
continuation of the treatment [62].
Recently,  genome analyzing technology such as 
liquid biopsy has been evolving rapidly; hence,  cancer 
gene profiles could soon be evaluable using blood drop-
let samples.  If liquid biopsy becomes widespread,  
treatment strategies will improve because it will be pos-
sible to evaluate and select treatment options in a more 
timely manner [63].
On the other hand,  delivering systemic chemo-
therapy is also essential to treat ALK-positive NSCLC 
patients.  Pemetrexed is reported to be effective for 
ALK-positive NSCLCs [64 , 65].  Park et al.  retrospec-
tively reported that pemetrexed monotherapy as a sec-
ond-line treatment showed a better overall response rate 
and mPFS in ALK-positive patients than in wild-type 
patients (29.0% vs. 11.8%; p = 0.013; 8.7 months vs. 1.9 
months; p < 0.001).  Hence,  pemetrexed-containing 
chemotherapy is the treatment option of choice when 
the tumor is resistant to ALK-TKIs.
Conclusions
We reviewed the pivotal clinical studies and mecha-
nisms of resistance to ALK-TKIs.  ALK-positive 
NSCLCs acquire resistance via various mechanisms,  
making it a heterogeneous disease.  Therefore,  it is 
essential to develop next-generation treatment strate-
gies,  such as using next-generation ALK-TKIs for sec-
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ondary mutations or combination therapy with ALK-
TKIs and other TKIs.
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